Sells heart-lung surgery equipment and related services to hospitals and surgical teams, and implanted nerve-stimulation systems for epilepsy and depression to healthcare providers.
10-K for FY2025, filed Feb 25, 2026LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products…View ↗
LivaNova’s Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver…View ↗
LivaNova’s marketing and sales strategy is focused on rapid, cost-effective delivery of high-quality products to a diverse group of…View ↗
Customers, mainly hospitals, healthcare institutions and distributors, pay for equipment and nerve-stimulation devices when customers receive the products; installation is paid for when provided, while service contracts are paid upfront or periodically over the contract term.
10-K for FY2025, filed Feb 25, 2026LivaNova generates revenue through contracts with customers consisting primarily of hospitals, healthcare institutions, and distributors.…View ↗
Cardiopulmonary products may include performance obligations associated with assembly and installation of equipment. Accordingly, LivaNova…View ↗
Technical services include installation, repair, and maintenance of cardiopulmonary equipment under service contracts or upon customer…View ↗
Neuromodulation products are comprised of neuromodulation therapy systems for the treatment of DRE and DTD. LivaNova’s Neuromodulation…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by reportable segment ↗$1.4B
10-K for FY2025, filed Feb 25, 2026
$1.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Cardiopulmonary
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
57%
FY2022: 50%
|
Cardiopulmonary, FY2025
$785.4M Sources
|
Sold outright |
|
Neuromodulation
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
43%
FY2022: 47%
|
Neuromodulation, FY2025
$592.8M Sources
|
Sold outright |
Hospitals, healthcare institutions and distributors are customers; LivaNova sells medical devices through direct sales representatives, agents and independent distributors.
10-K for FY2025, filed Feb 25, 2026
Not on paper. It lost $242.5M in FY2025, but brought in more cash than it spent: $173.3M of free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.30 to $4.40 (versus $4.20 to $4.30 prior), assuming a…View ↗
Growing. Revenue grew 34% in 4 years, from $1B in FY2021 to $1.4B in FY2025, about 8% a year.
Advanced Circulatory Support wound down
The older report described Advanced Circulatory Support as a separate business selling temporary life-support products; the latest report says the former segment was wound down and includes its non-cannula results in Other.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 25, 2026Our ACS segment is engaged in the development, production and sale of leading-edge temporary life support products. Our ACS products, which…View ↗
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate…View ↗
Competes with Terumo Medical, Maquet Medical Systems, Medtronic, Haemonetics, Spectrum Medical, and NeuroPace
10-K for FY2025, filed Feb 25, 2026LivaNova’s primary medical device competitors in the Cardiopulmonary and Neuromodulation product groups are Terumo Medical Corporation…View ↗
Loading...